1,895
Views
14
CrossRef citations to date
0
Altmetric
Research Paper

Database mining analysis revealed the role of the putative H+/sugar transporter solute carrier family 45 in skin cutaneous melanoma

ORCID Icon, , , , , , & show all
Pages 496-506 | Received 04 Jul 2021, Accepted 09 Jul 2021, Published online: 02 Aug 2021

References

  • Bc M, Yongky A, Le T, et al. Regulation of glucose metabolism - A perspective from cell bioprocessing. Trends Biotechnol. 2016;34(8):638–651.
  • LQ C, Cheung LS, Feng L, et al. Transport of sugars. Annu Rev Biochem. 2015;84:865–894.
  • Vitavska O, Wieczorek H. Putative role of an SLC45 H+/sugar cotransporter in mammalian spermatozoa. Pflugers Arch. 2017;469(11):1433–1442.
  • Srour M, Shimokawa N, Hamdan FF, et al. Dysfunction of the cerebral glucose transporter SLC45A1 in individuals with intellectual disability and epilepsy. Am J Hum Genet. 2017;100(5):824–830. .
  • Le L, Escobar IE, Ho T, et al. SLC45A2 protein stability and regulation of melanosome pH determine melanocyte pigmentation. Mol Biol Cell. 2020;31(24):2687–2702. .
  • Lin Y, Chen X, Yang Y, et al. Mutational analysis of TYR, OCA2, and SLC45A2 genes in chinese families with oculocutaneous albinism. Mol Genet Genomic Med. 2019;7(7):e00687. .
  • Kumar-Sinha C, Kalyana-Sundaram S, Chinnaiyan AM. SLC45A3-ELK4 chimera in prostate cancer: spotlight on cis-splicing. Cancer Discov. 2012;2(7):582–585.
  • Bai X, Moraes TF, Reithmeier RAF. Structural biology of solute carrier (SLC) membrane transport proteins.  Mol Membr Biol. 2017;34(1–2):1–32.
  • Rastrelli M, Tropea S, Rossi CR, et al. Melanoma: epidemiology, risk factors, pathogenesis, diagnosis and classification. Vivo. 2014;28(6):1005–1011.
  • Madden K, Kasler MK. Immune Checkpoint Inhibitors in Lung Cancer and Melanoma. Semin Oncol Nurs. 2019;35(5):150932.
  • Queirolo P, Boutros A, Tanda E, et al. Immune-checkpoint inhibitors for the treatment of metastatic melanoma: a model of cancer immunotherapy. Semin Cancer Biol. 2019;59:290–297.
  • Gao J, Aksoy BA, Dogrusoz U, et al. Integrative analysis of complex cancer genomics and clinical profiles using the cBioPortal. Sci Signal. 2013;6(269): pl1. .
  • Tomczak K, Czerwińska P, Wiznerowicz M. The Cancer Genome Atlas (TCGA): an immeasurable source of knowledge. Contemp Oncol (Pozn). 2015;19(1A):A68–A77.
  • Tang Z, Li C, Kang B, et al. GEPIA: a web server for cancer and normal gene expression profiling and interactive analyses. Nucleic Acids Res. 2017;45(W1):W98–W102.
  • DS C, Bashel B, Balasubramanya SAH, et al. UALCAN: a Portal for Facilitating Tumor Subgroup Gene Expression and Survival Analyses. Neoplasia. 2017;19(8):649–658. .
  • Li T, Fan J, Wang B, et al. TIMER: a web server for comprehensive analysis of tumor-infiltrating immune cells. Cancer Res. 2017;77(21):e108–e110. .
  • Reina-Campos M, Moscat J, Diaz-Meco M. Metabolism shapes the tumor microenvironment. Curr Opin Cell Biol. 2017;48:47–53.
  • DeBerardinis RJ, Chandel NS. Fundamentals of cancer metabolism.Sci Adv. 2016 [Published 2016 May 27];2(5):e1600200. .
  • Liberti MV, Locasale JW. The Warburg effect: how does it benefit cancer cells? [published correction appears in Trends Biochem Sci. 2016 Mar; 41(3):287][published correction appears in Trends Biochem Sci. 2016 Mar;41(3):287]. Trends Biochem Sci. 2016;41(3):211–218.
  • Pascale RM, Calvisi DF, Simile MM, et al. The Warburg Effect 97 Years after Its Discovery.Cancers (Basel). 2020 [Published 2020 Sep 30];12(10):2819. .
  • Schneebauer G, Mauracher D, Fiechtner B, et al. Transcript levels of members of the SLC2 and SLC5 families of glucose transport proteins in eel swimbladder tissue: the influence of silvering and the influence of a nematode infection. Fish Physiol Biochem. 2018;44(2):599–613.
  • Biswas SK. Metabolic Reprogramming of Immune Cells in Cancer Progression. Immunity. 2015;43(3):435–449.
  • Sciacovelli M, Frezza C. Metabolic reprogramming and epithelial-to-mesenchymal transition in cancer. FEBS J. 2017;284(19):3132–3144.
  • Luengo A, Gui DY, Vander Heiden MG. Targeting metabolism for cancer therapy. Cell Chem Biol. 2017;24(9):1161–1180.
  • Marzagalli M, Ebelt ND, Manuel ER. Unraveling the crosstalk between melanoma and immune cells in the tumor microenvironment. Semin Cancer Biol. 2019;59:236–250.
  • Leven C, Padelli M, Carré JL, et al. Immune checkpoint inhibitors in melanoma: a review of pharmacokinetics and exposure-response relationships. Clin Pharmacokinet. 2019;58(11):1393–1405.